IRCT20150221021168N3招募中3 期
A Comparison of Adjunctive Quetiapine Versus Adjunctive Haloperidol in Combination with Sodium Valproate for Treatment of Patients with Mania or Mixed Feature Bipolar I Disorder
niversity of social welfare and rehabilitation sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients of 18 years or above
- •Patients were diagnosed with Bipolar I disorder experiencing an episode of acute mania or mixed feature according to psychiatric interview
- •All participants voluntarily provided a written informed consent form
排除标准
- •History of Sensitivity to Sodium Valproate , Quetiapine and Haloperidol
- •History of Neurological , Cardiovascular , Respiratory, Blood , kidney, Hepatic , Endocrine, Immunological and other Systemic Disease
- •Pregnancy and Breastfeeding Period
- •HIV Positive and Uncontrolled Diabetic patients
- •Substance Use Disorders
- •History of Brain Blood Vessels Diseases and Head Trauma
研究者
相似试验
尚未招募
1 期
Comparison of Efficacy of Quetiapine Alone versus Quetiapine plus Lamotrigine in the Treatment of Depressive episode of Bipolar I and II DisorderBipolar depressionTCTR20230712005university of health sciences, lahore166
尚未招募
3 期
Quetiapine as an adjuvant for alcohol withdrawal deliriumCTRI/2024/07/069766Dr Jeel Vasa
已完成
3 期
Comparison of the effect of Quetiapine and Alprazolam on insomnia after coronary artery bypass graft sugeryInsomnia.Other insomniaG47.09IRCT20160716028945N4Esfahan University of Medical Sciences64
已完成
3 期
Effect of Quetiapine in Preventing Delirium in ICU Patientspatient admitted to the intensive care unit.Delirium due to known physiological conditionIRCT20180520039739N5Esfahan University of Medical Sciences98
进行中（未招募）
不适用
The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorders with or without Psychotic SymptomsPostpartum depressive disorders with or without psychotic symptomsEUCTR2006-006427-39-DEAstraZeneca GmbH